NASDAQ$PRME
Prime Medicine Inc · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Prime Medicine reported its financial results for the first quarter of 2025, highlighting advancements in its genetic therapy programs and providing business updates.
Prime Medicine reported a net loss of $51.9 million for the first quarter of 2025, an increase from $45.8 million in the same period last year. The company saw an increase in both R&D and G&A expenses, primarily due to expansion of laboratory space and personnel. Despite the loss, Prime Medicine is advancing its clinical programs, with initial data from its PM359 trial expected in 2025 and IND/CTA filings for Wilson's Disease and AATD targeted for 2026.
- Net loss for Q1 2025 was $51.9 million, compared to $45.8 million in Q1 2024.
- Research and Development expenses increased to $40.6 million in Q1 2025 from $37.8 million in Q1 2024.
- General and Administrative expenses rose to $13.3 million in Q1 2025 from $11.2 million in Q1 2024.
- Cash, cash equivalents, and investments stood at $144.256 million as of March 31, 2025.
Headline financials
Revenue & EPS history
Prime Medicine · Revenue · Quarterly
$1.45M
Forward guidance
Prime Medicine expects its current cash, cash equivalents, and investments to be sufficient to fund operating expenses and capital expenditure requirements into the first half of 2026.
Tailwinds
- Initial data from Phase 1/2 trial of PM359 for p47phox CGD expected in 2025.
- IND and/or CTA for PM577 for Wilson's Disease on-track for 1H 2026.
- IND and/or CTA filing targeted for mid-2026 for AATD program.
- Prime Editing technology has the potential to correct disease-causing mutations without introducing off-target or bystander edits.
- Company is committed to building a liver franchise of Prime Editors to cure major genetic diseases.
Headwinds
- Uncertainties related to Prime Medicine's product candidates entering clinical trials.
- Risks related to the development and optimization of new technologies.
- Preclinical studies or clinical studies not being predictive of future results.
- Uncertainties related to obtaining regulatory approvals.
- Risks associated with the scope of intellectual property protection.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 14 quarterly earnings reports · overlaid with Q1 2025
-1.7%
Avg return
Earnings day
-7.2%
Avg return
5 days after
-10.8%
Avg return
30 days after
29%
5 / 17 earnings
Positive
+26.6%
Q1 2025
Best reaction
-9.8%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -8.2% | -13.9% | -28.8% | |
| Q3 2025 | -9.1% | -15.1% | -10.5% | |
| Q1 2025 | +26.6% | -7.5% | +15.9% | |
| Q4 2024 | +4.1% | -4.5% | -17.8% | |
| Q3 2024 | -9.8% | -23.8% | -31.4% | |
| Q2 2024 | -4.5% | -2.5% | -19.3% | |
| Q1 2024 | +12.2% | +18.2% | +14.9% | |
| Q4 2023 | +1.6% | -2.4% | -18.9% | |
| Q3 2023 | +17.0% | +13.1% | +21.6% | |
| Q2 2023 | -7.5% | -14.9% | -13.3% | |
| Q1 2022 | -9.4% | -10.5% | +3.2% | |
| Q1 2023 | -9.4% | -10.5% | +3.2% | |
| Q4 2020 | -9.7% | -11.7% | -21.9% | |
| Q4 2022 | -9.7% | -11.7% | -21.9% | |
| Q3 2022 | -4.4% | -8.1% | -19.4% | |
| Q3 2021 | -4.4% | -8.1% | -19.4% | |
| Q4 2021 | -4.4% | -8.1% | -19.4% | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro